Bamco Inc. NY Reduces Position in DexCom, Inc. (NASDAQ:DXCM)

Bamco Inc. NY lowered its stake in DexCom, Inc. (NASDAQ:DXCM) by 41.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 564,854 shares of the medical device company’s stock after selling 401,618 shares during the period. Bamco Inc. NY owned 0.14% of DexCom worth $37,868,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in DXCM. Blue Whale Capital LLP lifted its position in DexCom by 91.9% during the 3rd quarter. Blue Whale Capital LLP now owns 236,000 shares of the medical device company’s stock worth $15,821,000 after acquiring an additional 113,000 shares during the period. Taylor Frigon Capital Management LLC lifted its holdings in shares of DexCom by 51.6% during the third quarter. Taylor Frigon Capital Management LLC now owns 32,554 shares of the medical device company’s stock worth $2,182,000 after purchasing an additional 11,075 shares during the period. Brooktree Capital Management purchased a new stake in DexCom in the third quarter valued at approximately $683,000. National Pension Service increased its holdings in DexCom by 4.1% in the 3rd quarter. National Pension Service now owns 949,743 shares of the medical device company’s stock worth $63,671,000 after buying an additional 37,363 shares during the period. Finally, Intact Investment Management Inc. purchased a new position in DexCom during the 3rd quarter worth approximately $650,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at DexCom

In related news, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the sale, the chief operating officer now directly owns 264,915 shares in the company, valued at approximately $18,318,872.25. This trade represents a 0.28 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Sadie Stern sold 426 shares of the business’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the transaction, the executive vice president now owns 75,451 shares in the company, valued at $5,217,436.65. The trade was a 0.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 5,431 shares of company stock valued at $399,319. Corporate insiders own 0.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Leerink Partners dropped their price objective on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. Oppenheimer cut their price target on DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Wells Fargo & Company boosted their price objective on DexCom from $80.00 to $90.00 and gave the company an “overweight” rating in a report on Friday, October 25th. Stifel Nicolaus raised their target price on DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, August 23rd. Finally, JPMorgan Chase & Co. lifted their price target on DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a research report on Friday, October 25th. Seven analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $104.59.

DexCom Stock Performance

Shares of NASDAQ:DXCM opened at $79.31 on Tuesday. The business’s 50 day moving average price is $71.58 and its 200-day moving average price is $87.18. The firm has a market capitalization of $30.98 billion, a PE ratio of 47.49, a P/E/G ratio of 2.38 and a beta of 1.17. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.